Idiopathic neutropenia after clonal and antigenic exclusion: A progesterone-dependent subtype

M Mark Orland (1Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH) C Carlos Bravo-Perez (1Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH) O Olisaemeka Ogbue (1Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland, United States) A Asfand Yar Cheema (1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States) A Aashray Mandala (1Department of Translational Hematology and Oncology Research, Cleveland, United States) S Serhan Unlu (2Cleveland Clinic, Cleveland, United States) Z Zachary Brady (1Department of Translational Hematology and Oncology Research, Cleveland, United States) C Carmelo Gurnari (1Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH) V Valeria Visconte (1Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH) J Jaroslaw Maciejewski (1Department of Translational Hematology and Oncology Research, Cleveland, United States)

Abstract

Abstract Chronic idiopathic neutropenia (CIN) is characterized by a persistently reduced absolute neutrophil count, typically <1.5×10⁹/L for ≥3 months, without identifiable infectious, nutritional, autoimmune, clonal, congenital, or drug-related causes. It most commonly affects adult women, carries a variable risk of infection, and is frequently managed expectantly in the absence of severe or recurrent infections. An index case of CIN with irregular menses and normalization of counts during pregnancy prompted an institution-wide review of adult neutropenia. U[p front we excluded cases of known congenital and drug-induced neutropenia. Among 238 presumed CIN patients, 88 had large granular lymphocytic (LGL) leukemia–associated neutropenia, 63 had autoimmune neutropenia defined by the presence of anti-neutrophil antibodies, and 87 met criteria for idiopathic neutropenia. Within the presumptive CIN group, extended blood antigen screening identified 12 patients with a Duffy-null phenotype, who were excluded from further idiopathic analysis (final n=75). This included 10 African American, 1 Caucasian, and 1 Asian patient. Extended blood-group profiling (Kidd, Colton, Lutheran, Dombrock, LW, ABO) showed no significant deviation from population frequencies. In the remaining non-Duffy CIN patients, remarkably 54/75 were female with a mean age of 45±16 years. At presentation, mean WBC was 2.84±0.58×10⁹/L and ANC was 0.92±0.39×10⁹/L, Hgb was 13.5±1.2g/dL and platelets were 229±83×10⁹/L. Antinuclear antibodies were assessed in 73 patients, with 63 negative and 10 positive, predominantly speckled (66%) but rheumatologic consultation did not yield systemic autoimmune diagnoses. Hypothyroidism was noted in two CIN cases. Irregular menses were reported in 50% of female CIN patients with documented histories, and among those, 80% exhibited higher or normal neutrophil counts during gestation. Physiologically, pregnancy is a progesterone-high state associated with neutrophilia and physiologic leukocytosis; in addition, progesterone can dampen cytotoxic T-cell activity and inflammatory signaling while supporting marrow niche function. Furthermore, progesterone binds PR on marrow stromal cells and can upregulate CSF3 (G-CSF) and possibly other hematopoietic growth factors, thus regulating granulopoiesis. By contrast, anovulatory or irregular cycles often reflect luteal progesterone deficiency, which may predispose susceptible patients to lower ANC prompting us to formulate a theory that excess of CIN in females may be due to a progesterone-responsive CIN subtype. From our cohort, there were no patients on progesterone-supplement to evaluate if there would be responsiveness secondary to its utilization. To further support this theory we turned to metanalytic resources. TriNetX1allowed us search and identify women receiving exogenous progesterone versus a control receiving non-hormonal contraceptives and assign to them a corresponding ANC. When we compared ANC in 1:1 greedy propensity-score matching to control for covariates (demographics, BMI, and disease confounders e.g., malignancy). balance between comparator groups was confirmed by standardized mean differences <0.10. After matching (n=18,561 per arm), the exogenous progesterone group had a significantly higher neutrophil count compared to non-hormonal contraception (1.9±3.7 vs 1.5±1.7; t=3.5, p=.0004). The cohort age range was similar to our patient population 44 ±19. Our observations motivate prospective evaluation of progesterone-high states as potential modifiers of ANC in otherwise idiopathic cases and particularly refractory cases Cycle-synchronized CBC with paired progesterone and estradiol measurements, together with controlled progesterone augmentation trials, can quantify ANC changes and clinical outcomes in this subset. We thank TriNetX and all participants for their contribution, without whom this research would not have been possible. ReferencesRobertson SA, Mayrhofer G, Seamark RF. Ovarian steroid hormones regulate granulocyte-macrophage colony-stimulating factor synthesis by uterine epithelial cells in the mouse. Biol Reprod. 1996 Jan;54(1):183-96. doi: 10.1095/biolreprod54.1.183. PMID: 8838016.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 2995-2995
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (10)

M

Mark Orland

1Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH

C

Carlos Bravo-Perez

1Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH

O

Olisaemeka Ogbue

1Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland, United States

A

Asfand Yar Cheema

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States

A

Aashray Mandala

1Department of Translational Hematology and Oncology Research, Cleveland, United States

S

Serhan Unlu

2Cleveland Clinic, Cleveland, United States

Z

Zachary Brady

1Department of Translational Hematology and Oncology Research, Cleveland, United States

C

Carmelo Gurnari

1Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH

V

Valeria Visconte

1Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH

J

Jaroslaw Maciejewski

1Department of Translational Hematology and Oncology Research, Cleveland, United States